Holos Life Sciences is a groundbreaking life sciences company specializing in the discovery and advancement of innovative epigenetic biomarkers. Our focus lies in utilizing the revolutionary EpiSwitch™ system, a clinically validated and patented discovery platform developed by our shareholder, Oxford Biodynamics Plc. This unique system enables us to develop biomarkers that have the potential to enhance health, wellness, and performance in both humans and animals, without resorting to pharmaceutical intervention.

As experts in integrative multi-omic data, we leverage the power of 3D genomics to predict and evaluate various indicators, including preventative healthcare, diagnostics, and performance optimization. Our proprietary platform, EpiSwitch™, is instrumental in uncovering chromosome conformation signature (CCS) biomarkers that are not only binary and stable but also possess predictive and prognostic value. Notably, leading pharmaceutical companies worldwide have conducted trials using EpiSwitch™, with results published in renowned scientific and medical journals.

At Holos, we firmly believe in the value of personalized and actionable health interventions. By continually measuring the impact of biological, environmental, and behavioral inputs on our epigenome using EpiSwitch™, we can derive precise and tailored insights. Our cutting-edge biomarkers, based on EpiSwitch™ signatures, are poised to revolutionize personalized healthcare and wellness outcomes.

Join us on this transformative journey towards a healthier future for all